Grants8 | The most comprehensive grants search on the web

Grant Analysis

Purpose & Target

This grant aims to accelerate the discovery and development of diverse biotherapeutic modalities for treating nervous and neuromuscular system disorders. - It supports projects from lead optimization through first-in-human clinical trials. - Target recipients are research teams led by Program Directors/Principal Investigators (PD/PIs) from various eligible organizations. - This grant is SECTOR-SPECIFIC. - Geographic scope includes both domestic (U.S.) and non-domestic (non-U.S.) entities. - Key filtering criteria: focus on biologics, nervous/neuromuscular system disorders, lead optimization to FIH clinical trial stage. - Grant frequency: Recurring, as a re-issue of a previous funding opportunity (PAR-21-163). - Program context: Part of NIH's Blueprint for Neuroscience Research, bridging the gap in biotherapeutics development by providing funding and in-kind resources like Contract Research Organizations (CROs) and consultants.

Financial Structure

Budget range: Not limited, but must reflect actual project needs.
Maximum funding: The UH3 phase cannot exceed four years, and the total duration of both UG3 and UH3 phases cannot exceed 5 years. Specific monetary amounts are not provided.
Eligible costs: Investigator-led discovery and development activities, regulatory meeting packages, and IND application assembly and filing costs.
Ineligible costs: Activities conducted by BPN Biologics CROs (as NIH covers these in-kind).
Matching fund requirements: None (no cost sharing required).
Co-financing requirements: None.
Payment schedule: Not detailed, implied to be based on annual reports.
Financial reporting requirements: Annual Research Performance Progress Report (RPPR) and financial statements; final RPPR, invention statement, and expenditure data for closeout.
Audit requirements: Subject to 2 CFR Part 200 (Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards).
Indirect cost policies: Not explicitly detailed, but standard NIH policies apply.
Financial guarantees: None specified.
Currency: Not specified, but generally USD for NIH grants.

Eligibility Requirements

Eligible Organization Types

Eligible for:
- Higher Education Institutions (Public/State Controlled, Private)
- Nonprofits (501(c)(3) IRS Status, Non-501(c)(3))
- For-Profit Organizations (Small Businesses, Other than Small Businesses)
- Local Governments (State, County, City/Township, Special District, Indian/Native American Tribal (Federally Recognized/Other))
- Federal Government (Eligible Agencies, U.S. Territory or Possession)
- Other: Independent School Districts, Public Housing Authorities/Indian Housing Authorities, Native American Tribal Organizations, Faith-based or Community-based Organizations, Regional Organizations, Non-domestic (non-U.S.) Entities (Foreign Organizations).

Geographic Requirements

Organizations from any country (domestic or non-U.S. entities) are eligible to apply.

Technical & Project Stage Requirements

Projects must focus on biotherapeutic modalities (e.g., antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies) for nervous/neuromuscular system disorders.
Projects must be at the Discovery Stage (one or more lead biologic agents identified, requiring no more than two years of optimization for clinical candidate selection, with preliminary target engagement and in vivo efficacy data) OR Development Stage (single clinical candidate selected, requires no further optimization, suitable pharmacokinetics, demonstrated in vivo target engagement and efficacy, protected by patents/pending patents).
PD/PI must dedicate at least 20% level of effort (2.4 person months) to the project.

Registration Requirements

Applicant organizations must be registered with:
- System for Award Management (SAM) - requires annual renewal.
- NATO Commercial and Government Entity (NCAGE) Code (for foreign organizations, in lieu of CAGE code).
- Unique Entity Identifier (UEI) - issued as part of SAM.gov registration.
- eRA Commons - for organization and all PD(s)/PI(s).
- Grants.gov.

Exclusion Criteria

Not responsive:
- Basic research and studies of disease mechanism.
- Animal model development and/or validation.
- Mechanistic studies for how the proposed therapeutic acts at its target.
- Stand-alone preclinical efficacy studies in animal models.
- Development of in vitro screening assays for activity or selectivity.
- Development of small molecule therapeutics.
- Development of diagnostics and medical devices.
- Development of risk, diagnostic, prognostic, predictive, and safety biomarkers.
- Stand-alone clinical trials.
- Studies directed beyond a first-in-human (FIH) phase 1 study.
- Natural history clinical studies.
Applications with substantial overlap with other applications under review or appeal are not accepted.

Application Process

Application Timeline

Latest Application Due Date: July 15, 2027 by 5:00 PM local time of applicant organization.
Letter of Intent Due Date(s): 30 days prior to each application due date (e.g., June 15, 2027 for July 15, 2027 submission).
Earliest Submission Date: December 27, 2024.
Grant Expiration Date: August 19, 2027.
Award Project Period: UG3 phase up to 2 years, UH3 phase up to 4 years, total duration up to 5 years.

Submission Process

Submission Platform: Electronically via NIH ASSIST system, institutional system-to-system (S2S) solution, or Grants.gov Workspace.
Required Registrations (prior to submission): SAM, NCAGE (for foreign), UEI, eRA Commons (organization and PD/PI), Grants.gov.
Pre-Application Consultation: Strongly encouraged to contact NIH Scientific/Research staff at least 12 weeks before a receipt date. Mandatory for applications requesting $500,000 or more in direct costs in any single year (contact 8 weeks prior).

Required Documentation & Materials

Standard Forms: SF424(R&R) Cover, Project/Performance Site Locations, Other Project Information, Senior/Key Person Profile, R&R Budget, Subaward Budget, PHS 398 Cover Page Supplement, PHS 398 Research Plan, PHS Human Subjects and Clinical Trials Information (if applicable), PHS Assignment Request Form.
Specific Attachments:
- Gantt Chart (1 page max): Project timeline showing UG3 and UH3 activities, distinguishing PD/PI vs. BPN Biologics CRO activities.
- Intellectual Property (IP) Strategy (2 pages max): Describe constraints, list patents, plans for future IP filings, infrastructure for IP management, and IP sharing for multi-institutional applications.
- Specific Aims: Must include aims for both UG3 and UH3 phases, including IND preparation/filing. If FIH clinical trial proposed, define aims.
- Research Strategy: Subsections required:
  - Clinical Impact (Significance): Describe disease state, unmet need, current efforts, and include a Target Product Profile (TPP) table.
  - Biological Rationale and Therapeutic Agent Profile (Significance): Evidence linking target to disease, and include a Therapeutic Agent Profile Table. Must state if entering at Discovery or Development stage and provide evidence meeting entry criteria.
  - Innovation: Discuss novelty and differentiation.
  - Approach: Detail experimental designs for PD/PI-led activities; high-level for BPN Biologics CRO activities. Include assay validation, animal model validation, testing funnel (Discovery stage), remaining UG3 activities (Development stage), plans for nonclinical/manufacturing/clinical studies.
- Letters of Support: Required from consultants/contractors/collaborators not provided by NIH, and from the institution's technology transfer official (if applicable). For private entities providing agents, a letter addressing limits on studies/data sharing/licensing from a high official.
- Data Management and Sharing Plan: Required for all applications.
- Appendix: Limited to blank questionnaires/surveys. Summary of FDA meeting outcomes (2 pages max) if applicable.

Post-Award Requirements & Reporting

Reporting: Annual Research Performance Progress Report (RPPR), financial statements. Final RPPR, invention statement, and expenditure data for closeout.
Monitoring: Bi-weekly Lead Development Team (LDT) meetings. Annual milestone updates to External Oversight Committee.
Data Management: Deposit project-related data, study designs, and protocols in a centralized, secure BPN Biologics database.
Clinical Trial Compliance (if applicable): Registration and results submission on ClinicalTrials.gov. IRB/IEC approval and provision of documents for major changes. Data and safety monitoring. IND/IDE requirements.

Evaluation Criteria

Overall Impact

Likelihood for the project to exert a sustained, powerful influence on the research field(s) involved.
Assessment considers unmet medical need, potential patient benefit, competitive landscape, biological rationale, potential for safe/effective clinical candidate, and strengths/weaknesses of PD/PI-directed studies.

Importance of the Research (Factor 1 - Scored)

Significance:
- Addresses an important gap, solves a critical problem, or creates a valuable advance.
- Rationale and rigor of scientific background justify the study.
- Alignment of Target Product Profile (TPP) goals with clinical practice.
- Clear path into the clinic for the proposed therapy.
- Strength of data supporting biological rationale.
- For Discovery stage: strength of in vitro and in vivo data for leads.
- For Development stage: strength and completeness of data for clinical candidate (activity, PK, PK-PD, preliminary safety/tolerability).
Innovation:
- Novelty of proposed therapeutic approach, biological target/pathway, assays, or models.
- Expected improvement in clinical outcomes (efficacy, safety, reduced patient burden) over existing treatments.
- Differentiation from similar agents (in development or marketed).

Rigor and Feasibility (Factor 2 - Scored)

Rigor:
- Potential to produce unbiased, reproducible, robust data.
- Rigor of experimental design, appropriate controls, sufficient sample size.
- Quality of plans for analysis, interpretation, and reporting.
- Adequacy of plans to address relevant biological variables (sex, age).
- For human subjects/animals: rigor of intervention, justified outcome variables, generalizability/relevance, diverse population.
Feasibility:
- Soundness and achievability of the proposed approach, including problem-solving plans.
- For Discovery stage: suitability of biologic agent(s) for optimization into a drug candidate within two years. Suitability of assays and advancement criteria. Bioactivity assay validation strength.
- For Development stage: adequacy of UG3 activities to address remaining deficiencies and enable IND-enabling studies within one year.
- For PD/PI-led IND-enabling/manufacturing: whether plans include appropriate studies and realistic timelines.
- For human subjects: adequacy and feasibility of recruitment/retention plan.

Expertise and Resources (Factor 3 - Scored)

Investigator(s):
- Demonstrated background, training, and expertise.
- For MPI: quality of leadership plan for coordination.
- If PD/PI performs work also done by BPN CROs: evaluate expertise and environment.
- PD/PI's leadership experience suitable for managing activities and collaborating with NIH.
Environment:
- Appropriate institutional resources for successful execution.

Additional Review Criteria (Not Scored)

Intellectual Property (IP):
- Adequacy of description of IP landscape and how barriers are addressed.
- How IP Strategy attachment and letters of support address concerns.
- Known constraints impacting development.
- Appropriateness of IP filing plans for current stage.
- IP sharing clearly addressed if multiple institutions involved.
Protections for Human Subjects: Justification for involvement, adequacy of protection, benefits, knowledge gain, data/safety monitoring. Justification for exemption.
Vertebrate Animals: Description of procedures, justification for use/species, interventions for discomfort, justification for euthanasia method.
Biohazards: Evaluation of hazards and proposed protections.
Authentication of Key Biological and/or Chemical Resources: Plans for identifying and ensuring validity.
Budget and Period of Support: Justification and reasonableness in relation to proposed research.

Compliance & Special Requirements

Regulatory Compliance

FDA Regulations: IND-enabling nonclinical studies must comply with GLP (Good Laboratory Practices). Investigational products for clinical trials must be produced under cGMP (current Good Manufacturing Practices). Clinical trials must follow GCP (Good Clinical Practices) and FDA guidelines.
Clinical Trials: If applicable, requires registration and results reporting on ClinicalTrials.gov.
Human Subjects: Requires IRB or Independent Ethics Committee (IEC) approval. Adherence to 45 CFR Part 46 protections.
Vertebrate Animals: Adherence to guidelines for care and use.

Data & Intellectual Property (IP)

Data Management & Sharing: Compliance with the 2023 NIH Policy for Data Management and Sharing. Data deposited in a centralized, secure BPN Biologics database.
Intellectual Property: Recipient institutions retain rights to existing IP and are assigned rights to any new IP developed within the program. Expected to file and maintain IP, and develop commercialization plans. NIH-contracted consultants/CROs assign IP rights to the recipient institution. Data will be considered confidential and business privileged information of the recipient.

Project Structure & Oversight

Cooperative Agreement: Involves substantial NIH programmatic involvement. NIH staff assist, guide, coordinate, and participate. PD/PI retains primary responsibility, but works closely with a 'Lead Development Team' (LDT) including NIH staff and NIH-contracted consultants.
Milestone-Driven: Progression (e.g., UG3 to UH3 transition, clinical trial initiation) is contingent upon successful achievement of agreed-upon milestones and administrative review by NIH. Failure to meet milestones may result in discontinued funding or access to CRO resources.
In-Kind Resources: Optional access to NIH-funded Contract Research Organizations (CROs) for manufacturing, nonclinical studies, and early phase clinical trials, and NIH-contracted consultants with industry/regulatory experience. Costs for these CROs are covered by NIH, not the applicant's grant budget.

Special Considerations

Focus: Exclusively on biotherapeutics for nervous and neuromuscular system disorders. Small molecules and diagnostics are specifically excluded.
Rigor & Transparency: Strong emphasis on rigorous and robust supporting data, unbiased experimental design, and transparent reporting as per NIH guidance.
Budget: While budgets are not limited, equipment requests are generally not encouraged and should be fully justified and essential.
Mandatory Disclosure: Recipients must disclose any federal criminal law violations involving fraud, bribery, or gratuity potentially affecting the federal award.

Grant Details